Ken Ogasawara

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 23

Top Venues

Cancer chemotherapy and pharmacology

Blood

Clinical pharmacology and therapeutics

Clinical pharmacokinetics

Oak Ridge Institute for Science and Education

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Oak Ridge Institute for Science and Education Jun 05 2017 - May 31 2018

United States

Research Participation Program in the Food and Drug Administration at CDER

Publications

Ming Chang, Yizhe Chen, Ken Ogasawara, Brian James Schmidt, Lu Gaohua
Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19. Cancer chemotherapy and pharmacology (2024)
Michael L Wang, Tanya Siddiqi, Leo I Gordon, Manali Kamdar, Matthew Lunning, Alexandre V Hirayama, Jeremy S Abramson, Jon Arnason, Nilanjan Ghosh, Amitkumar Mehta, Charalambos Andreadis, Scott R Solomon, Ana Kostic, Christine Dehner, Ricardo Espinola, Lily Peng, Ken Ogasawara, Amy Chattin, Laurie Eliason, Maria Lia Palomba
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Hardik Mody, Ken Ogasawara, Xu Zhu, Dale Miles, Prathap Nagaraja Shastri, Jochem Gokemeijer, Michael Z Liao, Sreeneeranj Kasichayanula, Tong-Yuan Yang, Nagendra Chemuturi, Swati Gupta, Vibha Jawa, Vijay V Upreti
Best Practices & Considerations for Clinical Pharmacology & Pharmacometric Aspects for Optimal Development of CAR-T & TCR-T Cell Therapies: An Industry Perspective. Clinical pharmacology and therapeutics (2023)
Yizhe Chen, David Wyatt, Massimo Attanasio, Mark Thomas, Michael Thomas, Bing He, Rina Nishii, Liangang Liu, Vivian Shan, Yongjun Xue, Leonidas N Carayannopoulos, Ken Ogasawara, Gopal Krishna
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults. Cancer chemotherapy and pharmacology (2023)
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew A Lunning, Michael L Wang, Jon E Arnason, Enkhtsetseg Purev, David G Maloney, Charalambos Babis Andreadis, Alison Sehgal, Scott R Solomon, Nilanjan Ghosh, Christine Dehner, Yeonhee Kim, Ken Ogasawara, Ana Kostic, Tanya Siddiqi
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood (2023)
Jochem Gokemeijer, Nanda Balasubramanian, Ken Ogasawara, Joanna Grudzinska-Goebel, Vijay V Upreti, Hardik Mody, Siddha Kasar, Venkata R Vepachedu, Weifeng Xu, Swati Gupta, Edit Tarcsa, Robert Dodge, Kate Herr, Tong-Yuan Yang, Sophie Tourdot, Vibha Jawa
An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment aspects of CAR-T and TCR-T Cellular Therapies Development. Clinical pharmacology and therapeutics (2023)
Shinichi Makita, Go Yamamoto, Dai Maruyama, Yuki Asano-Mori, Daisuke Kaji, Revathi Ananthakrishnan, Ken Ogasawara, Lara Stepan, Claudia Schusterbauer, Nils Rettby, Jens Hasskarl, Koji Izutsu
Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Cancer medicine (2022)
Jeremy S Abramson, Scott R Solomon, Jon E Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim G N J Mutsaers, Francisco J Hernandez-Ilizaliturri, Koji Izutsu, Judith Trotman, Matthew A Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. Blood (2022)
Jeremy S Abramson, Scott R Solomon, Jon E Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim G N J Mutsaers, Francisco J Hernandez-Ilizaliturri, Koji Izutsu, Judith Trotman, Matthew A Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. Blood (2022)
Ken Ogasawara, James Lymp, Timothy Mack, Justine Dell'Aringa, Chang-Pin Huang, Jeff Smith, Leanne Peiser, Ana Kostic
In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma. Clinical pharmacology and therapeutics 112 (1) (2022)
Yizhe Chen, Ken Ogasawara, Rebecca Wood-Horrall, Mark Thomas, Michael Thomas, Bing He, Liangang Liu, Yongjun Xue, Sekhar Surapaneni, Leonidas N Carayannopoulos, Simon Zhou, Maria Palmisano, Gopal Krishna
Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults. Cancer chemotherapy and pharmacology 90 (4) (2022)
Amer M Zeidan, Isaac Boss, C L Beach, Wilbert B Copeland, Ethan Thompson, Brian A Fox, Vanessa E Hasle, Ken Ogasawara, James Cavenagh, Lewis R Silverman, Maria Teresa Teresa Voso, Andrzej Hellmann, Mar Tormo, Tim O'Connor, Alessandro Previtali, Shelonitda Rose, Guillermo Garcia-Manero
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood advances 6 (7) (2022)
Ken Ogasawara, Rebecca N Wood-Horrall, Mark Thomas, Michael Thomas, Liangang Liu, Mary Liu, Yongjun Xue, Sekhar Surapaneni, Leonidas N Carayannopoulos, Simon Zhou, Maria Palmisano, Gopal Krishna
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach. Cancer chemotherapy and pharmacology 88 (6) (2021)
Tanya Siddiqi, Jacob D Soumerai, Kathleen A Dorritie, Deborah M Stephens, Peter A Riedell, Jon E Arnason, Thomas J Kipps, Heidi H Gillenwater, Lucy Gong, Lin Yang, Ken Ogasawara, Jerill Thorpe, William George Wierda
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood (2021)
Ken Ogasawara, Nastya Kassir, Xiaomin Wang, Bouchra Benettaib, Simon Zhou, Maria Palmisano, Yan Li
Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure-response analysis of pomalidomide. Pediatric research 90 (4) (2021)
Ken Ogasawara, Michael Dodds, Timothy Mack, James Lymp, Justine Dell'Aringa, Jeff Smith
Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma. Clinical pharmacokinetics 60 (12) (2021)
Ken Ogasawara, Jeanelle Kam, Mark Thomas, Liangang Liu, Mary Liu, Yongjun Xue, Sekhar Surapaneni, Leonidas N Carayannopoulos, Simon Zhou, Maria Palmisano, Gopal Krishna
Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants. Cancer chemotherapy and pharmacology 88 (3) (2021)
Ken Ogasawara, Kathryn Newhall, Stephen E Maxwell, Justine Dell'Aringa, Vitalina Komashko, Nurgul Kilavuz, Richard Delarue, Myron Czuczman, Lars Sternas, Shelonitda Rose, C L Beach, Steven Novick, Simon Zhou, Maria Palmisano, Yan Li
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies. Clinical pharmacokinetics 59 (2) (2021)
Ken Ogasawara, Christine Xu, Vanaja Kanamaluru, Maria Palmisano, Gopal Krishna
Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects. Cancer chemotherapy and pharmacology 85 (5) (2020)
Ken Ogasawara, William B Smith, Christine Xu, Jian Yin, Maria Palmisano, Gopal Krishna
Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment. Cancer chemotherapy and pharmacology 85 (6) (2020)
Ken Ogasawara, Patricia M LoRusso, Anthony J Olszanski, Olivier Rixe, Christine Xu, Jian Yin, Maria Palmisano, Gopal Krishna
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. Cancer chemotherapy and pharmacology 86 (1) (2020)
Ken Ogasawara, Simon Zhou, Gopal Krishna, Maria Palmisano, Yan Li
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia. Cancer chemotherapy and pharmacology 84 (4) (2019)
Ken Ogasawara, Kimberly MacGorman, Liangang Liu, Jian Chen, Leonidas N Carayannopoulos, Simon Zhou, Maria Palmisano, Yan Li
Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects. Journal of clinical pharmacology 59 (12) (2019)

Ken Ogasawara.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Ken Ogasawara